BIIB

A MAJOR WEALTH GENERATION OPPORTUNITY IS AHEAD IN ALZHEIMER’S DRUGS

By Nigam Arora & Dr. Natasha Arora For the first time in two decades, the FDA has approved a new Alzheimer’s drug.  The drug is  from Biogen (BIIB).  There is a great unmet need for Alzheimer’s treatment.   Can you imagine investors getting richer by correctly buying the stocks of companies

Read More

A NEW PROMISING DRUG FOR ALZHEIMER’S — OPPORTUNITY FOR INVESTORS

Alzheimer’s Alzheimer’s is a terrible disease.  A new patient is diagnosed with Alzheimer’s in the United States every 65 seconds.  More than 5.8 million Americans are living with Alzheimer’s.  For those who are over 65, one in 10 has Alzheimer’s dementia. There is no cure.  Now a new treatment is

Read More

A MENACING PATTERN HAS REVEALED ITSELF IN THE STOCK MARKET $FB $AAPL $AMZN $NVDA $AMD $TSLA $INTC $EXPE $XOM $AMGN $AMAT $WDC $EA

Prudent investors ought to pay attention to a menacing pattern developing in the stock market. Please click here for an annotated chart. The chart is of the Nasdaq 100 ETF QQQ,  A similar pattern can be seen in S&P 500 ETF SPY,  I picked QQQ because the pattern is more

Read More

ACORDA THERAPEUTICS (ACOR) AND BIOGEN (BIIB) RUMOR MONGERS OUT IN FORCE

Acorda Therapeutics (ACOR)  rumor spreaders are out in force. They are misleading the uninformed investors about a statement Biogen  (BIIB) just made at a conference. We have taken partial profits on Acorda  at $30.20. Our highest short tranche in Acorda  is from $33.48. The rumor related to Biogen  buying Acorda

Read More

Do you want to gain an edge in the markets? Join thousands of your fellow investors and money managers to subscribe to Generate Wealth newsletter.

FREE FOREVER

Follow The Most Accurate Stock Market Analysis

Unrivaled Insights
In Bull and Bear Markets

Generate Wealth Newsletter
Free Forever

Generate Wealth Newsletter
Free Forever